Drugs / INT-1B3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04675996 | Dec 2020 → Mar 2023 | cancer | InteRNA | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT-1B3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04675996 ↗ |
| Modality | Oligonucleotide (other) | “lipid nanoparticle formulated microRNA (miR-193a-3p) mimic” NCT04675996 ↗ |
| Route | Intravenous | “60-min i.v. infusions twice per week in 21-day cycles” NCT04675996 ↗ |